News for PRPO Stock

Precipio Enters Into Agreement With Warrant Holder To Exercise Majority Of Warrants As Cashless Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting Precipio Announces its Q1-2025 Financial Results Precipio Announces Q1-2025 Shareholder Update Call Precipio Announces Q4 and year-end 2024 Shareholder Update Call Precipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited) Precipio grants senior management performance-based awards instead of traditional time-vested ESOPs Precipio Announces Q3-2024 Shareholder Update Call Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping Precipio Announces Employee Stock Option Plan Repricing Precipio Announces Q2-2024 Shareholder Update Call Precipio Reports $0.3M cash generated by operations (unaudited) in Q2-2024, as the company advances towards breakeven Precipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024 Precipio Inc. Announces Adjournment of Annual Meeting of Stockholders Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting Precipio Provides Status Update on Current Business Matters Precipio Secures a short-term $500K Credit Facility Precipio Announces Year end 2023 Shareholder Update Call Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer Precipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan Precipio Announces Christina Valauri joins the Board of Directors Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024 Precipio Announces Q3-2023 Shareholder Update Call Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022 Precipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023 Precipio Continues to Sign New HemeScreen™ Customers Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven Precipio Takes Final Step Towards Regaining Nasdaq Compliance Precipio’s Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan Precipio Announces Q2-2023 Shareholder Update Call Precipio Launches Its Much-Anticipated Quantitative BCR-ABL 2.0 Panel Precipio’s Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards Breakeven Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023 Precipio’s Omnia™ Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement Projected cash burn reduced by $1.5 million annually from Three Operational Efficiency Projects Precipio’s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology Precipio Shares Growth Catalysts For HemeScreen Precipio Announces Q1-2023 Shareholder Update Call Precipio Adds Substantial Pathology Customer to its Diagnostic Services Division Precipio Signs Another HemeScreen™ Customer Precipio Granted 180-day Extension From NASDAQ To Regain Compliance Precipio Unaudited Q1-2023 Product Revenues Exceed The Two Prior Quarters (Q3+Q4 of 2022) Combined Precipio Announces 2022 Fourth Quarter and Year-End Shareholder Update Call Precipio Ships First IV-Cell® Order to Major US Healthcare System CORRECTION -- Precipio continues to sign up and onboard HemeScreen™ customers Precipio continues to sign up and onboard HemeScreen™ customers ThermoFisher Salesforce Votes Precipio’s HemeScreen® as “Best New Product” Precipio Signs Another Major HemeScreen™ Customer Precipio Signs Additional Major HemeScreen™ Customer Precipio Presents Poster on HemeScreen® Study at Association of Molecular Pathology (AMP) 2022 Annual Conference Precipio Announces Third Quarter Shareholder Update Call Precipio Signs Agreement with Another Major US Healthcare Distributor for HemeScreen™ Sharon Robins Joins Precipio’s Products Division as Senior Director of Laboratory & Hospital Sales Precipio Launches New 1-Step Technology for all HemeScreen Assays Toni-Ann Mills Joins Precipio’s Products Division to Lead Channel Partner Training, Learning & Development Precipio Announces Second Quarter Shareholder Update Call Precipio to distribute HemeScreen® through Fisher Healthcare channel Precipio requests that all Stockholders that have not yet voted, proceed to cast their vote Keith Meadors Joins Precipio to Lead its Products Division Precipio Receives CE-IVD Certification to Market Multiple HemeScreen® Panels in Europe Precipio Signs First IV-Cell Customer Agreement Precipio customer American Oncology Network (AON) selected to present HemeScreen® technology case study at Industry leading clinical laboratory conference Precipio Announces 2021 Fourth Quarter and Year-End Shareholder Update Call Precipio Inc. Announces the Resignation of its Chief Financial Officer and Appointment of Interim CFO Precipio Releases Year-End 2021 Preliminary Unaudited Results and Outlook for 2022 New York State Approves Precipio’s HemeScreen for POL clinical use Precipio Announces Q3-2021 and year-end Shareholder Update Call American Oncology Network Partners with Precipio to Bring HemeScreen® into AON’s Laboratory Precipio Reschedules Q2-2021 Shareholder Update Call Precipio Corrects Announcement of Q2-2021 Shareholder Update Call Precipio Announces Q2-2021 and year-end Shareholder Update Call Precipio Announces Preliminary Unaudited Q2-2021 Revenues of $2.3M Precipio Terminates its Equity Line Precipio Launches HemeScreen® Anemia Panel, a One-of-its-Kind Testing Tool Precipio Announces Q1-2021 and year-end Shareholder Update Call Precipio Launches New HemeScreen Panel for AML, with an unparalleled 4-hour turnaround-time Precipio Launches its Rapid COVID-19 Antibody test on Amazon Platform Current Signed Customers Expected to Generate $1M Annualized Reported Revenues from Precipio’s HemeScreen POL Offering by Q4-2021 Precipio Enters Into an At-The -Market (ATM) Financing Arrangement Precipio Announces 95% Annual Growth YoY and 180% Quarterly Growth YoY Precipio Announces Q4-2020 and year-end Shareholder Update Call Mr. Ron Andrews joins Precipio’s Board of Directors Mr. Richard Sandberg is appointed Chairman of Precipio’s Board of Directors Precipio Launches COVID-19 Antibody Testing at Point-of-Care Precipio Signs HemeScreen™ Deals with Two Leading Oncology Groups Precipio Signs Sales & Marketing Agreement for HemeScreen™ with Major Oncology Distributor Precipio Announces Q3-2020 Shareholder Update Call Precipio & ADS Biotec Launch Seven Beta sites for IV-Cell™ Precipio Launches its Proprietary HemeScreen™ AML (Acute Myeloid Leukemia) Molecular Panel Precipio Announces a Shareholder Call to Discuss its COVID-19 Progress and Future Plans Precipio & ADS Biotec Sign Global Distribution Agreement for IV-Cell™ Precipio Announces Q2-2020 Corporate Update Call For Shareholders Precipio Adds Another HemeScreen™ Customer Precipio Announces Q1-2020 Corporate Update Call For Shareholders Precipio Announces Commercial Launch of COVID-19 Antibody Test Precipio Regains Listing Compliance with NASDAQ Minimum Bid Requirement Q1-2020 Net Revenues increase 77% over Q4-2019 to $1.2M Precipio Launches Covid-19 Antibody Test in its CLIA laboratory Precipio Announces Q2-2020 Unaudited Pathology Services Revenue Increased Approximately 50% over Q1’20